Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy.
Department of Surgery, Sapienza University of Rome, Rome, Italy.
Curr Mol Pharmacol. 2024;17:e18761429310703. doi: 10.2174/0118761429310703240823045808.
In the last decade, immunotherapy (IT) has revolutionized oncology and found indications in many cancers, including hepatocellular carcinoma (HCC). In HCC, IT has become the leading systemic therapy for advanced diseases. At the same time, it carries the promise of being a valuable therapy in other settings, including intermediate-stage and unresectable disease, as a downstaging or conversion modality. More controversial is the role of IT in relationship to liver transplantation (LT): on one side, it could be a helpful tool to control or downstage HCC before LT or to treat tumor recurrence after LT, while on the other, it carries the risk of graft rejection and graft loss. This review aims to cover these concerns in depth and unravel the current literature.
在过去的十年中，免疫疗法（IT）彻底改变了肿瘤学，并在许多癌症中找到了适应症，包括肝细胞癌（HCC）。在 HCC 中，IT 已成为晚期疾病的主要系统治疗方法。与此同时，它有望在其他情况下成为一种有价值的治疗方法，包括中晚期和不可切除的疾病，作为降期或转化的方式。更具争议的是 IT 在与肝移植（LT）的关系中的作用：一方面，它可以作为在 LT 前控制或降期 HCC 或治疗 LT 后肿瘤复发的有用工具，而另一方面，它存在移植物排斥和移植物丢失的风险。本综述旨在深入探讨这些问题，并梳理当前的文献。
